ir para o conteúdo principal
Logo Default

IPO Lisboa

IPO Lisboa

Institution Description

Established in 1923, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa) is a reference hospital for the treatment, education and research in the field of Oncology.

IPO Lisboa is the main cancer centre in the South of the country. It receives one fourth of the cancer patients in its area of influence – Greater Lisbon Region, Ribatejo, Alentejo, Algarve and the Autonomous Regions of Azores and Madeira, which covers a population of nearly five million inhabitants.

IPO Lisboa is a National Health Service (SNS) public hospital, which provides highly specialized health care and enjoys great social, medical, technical, academic and scientific prestige capital. It is very much cherished by patients and their family members, who highlight and value the humanist provision of health care, which is the unique brand of this institution.

 

 

IPO Lisboa in figures

With about 2.130 professionals – including 380 doctors, 625 nurses, 260 healthcare technicians – in 2024 IPO Lisboa had 264 beds available and treated nearly 60 thousand patients each year.

In 2024, the Institute welcomed 12.688 new patients, held 334.738 medical and 147.039 non-medical appointments, and performed 8.964 surgeries. In the area of bone marrow transplantation, the hospital performed 54 autologous, 55 allogeneic, 22 Car-T cells and 8 DLI (Donor Lymphocyte Infusion) transplant procedures. In addition to these figures, 76.288 radiotherapy treatments, 43.579 chemotherapy sessions, 7.575 nuclear medicine exams, 116.059 radiology exams, 43.050 day hospital sessions were carried out and 3.031 households were visited.

The paediatric department of IPO Lisboa registered 161 new cases of childhood cancer and kept monitoring 1.467 throughout the year.

In the research field (clinical and translational), IPO Lisboa has various ongoing programs in priority oncology areas, such as aggressive tumours and familial cancer. promoting around 250 projects every year, including both observational studies and clinical trials.

Patients’ referral to IPO Lisboa is carried out mainly through health centres and public and private hospitals, within its area of influence. However, due to the human resources, available techniques and technologies' high degree of specialization and differentiation, patients of all regions of the country, are referred and treated in the Institute, when it comes to more complex medical conditions and rare tumours.

IPO Lisboa also guarantees the principle of free choice and movement of patients, according to the rules in force with NHS and the average response times.

 

 

Certified hospital

Following the setting up of Reference Centres (RC) by the Ministry of Health (MH), IPO Lisboa is the RC for paediatric oncology and oesophageal, testicular, rectal, anal canal cancers and sarcomas of the soft parts and bones, in the field of adults' oncology.

The accreditation of the RC's is an ongoing process. IPO Lisboa fulfils the required conditions to become a RC in other oncological diseases, and it is waiting only for the MH to open the respective applications.

IPO is also certified by Agencia de Calidad Sanitaria de Andalucia, according to the model adopted by the MH for health services accreditation.

At an international level, the Institute is accredited by Organization of European Cancer Institutes (OECI) as a Clinical Cancer Centre, and European Society for Medical Oncology (ESMO) as an Integrated Oncology and Palliative Care Centre.

IPO Lisboa is also certified by the European reference networks such as European Reference Network Paediatric Cancer (PaedCan ERN) and European Network for Rare Adult Solid Cancer (EURACAN), regarding some of the adults' pathologies.

 

 

Investments

Last years' investments have allowed to care for and to treat more patients; The Paediatric and Adult Day Hospital, the Operating Theatre, the Bone Marrow Transplant Unit, the Immunohemotherapy Service were enlarged and remodelled, and the technological equipping of the Radiotherapy, Radiology, Nuclear Medicine, Clinical Pathology, Molecular Diagnosis Laboratories and Endoscopic Techniques Units continued.

Among the investments for 2025, we highlight the renovation of the Pathological Anatomy Laboratory. The works of the project for a new outpatient consultations building, near Praça de Espanha, are underway.

 

 

Our committment

IPO Lisboa aims at being at the forefront of medical and scientific knowledge and to keep on being NHS reference model with health care provision, undergraduate and post-graduate education and research in the oncology field.

We aim at creating more value, respecting the patients' rights and according to scientific, humanization, motivation and belonging principles for the citizens and the professionals.

 

__

Source: CI-IPO Lisboa, PACG, 09/04/2025.

Year

Download
General Indicators
No. of active clinical studies by study type
  • 62
    Active Clinical Trials
  • 266
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 19
    Clinical Trials initiated
  • 62
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 771
    No. of publications in indexed journals - last 5 full years
  • 100
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 279
    No. of available beds in the institution
  • 360
    No. of Physicians in the Institution
  • 571
    No. of Nurses in the Institution
  • 19
    No. of Pharmacists in the Institution
  • 4600 thousand
    No. of Inhabitants covered by the institution
    *South and islands of Portugal plus PALOP
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 60
    Researchers
  • 10
    Managers, Administrative, Legal and Financial
  • 4
    Study coordinators
  • 3
    Nurses
  • 1
    Pharmacists
Efficiency Indicators
  • 26
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 67%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 37 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 14 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices
    (SD=13 days)
General Indicators
No. of active clinical studies by study type
  • 64
    Active Clinical Trials
  • 247
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 4
    Clinical Trials initiated
  • 64
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 702
    No. of publications in indexed journals - last 5 full years
  • 100
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 285
    No. of available beds in the institution
  • 386
    No. of Physicians in the Institution
  • 588
    No. of Nurses in the Institution
  • 20
    No. of Pharmacists in the Institution
  • 4600 thousand
    No. of Inhabitants covered by the institution
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 52
    Researchers
  • 11
    Managers, Administrative, Legal and Financial
  • 4
    Study coordinators
  • 3
    Nurses
  • 1
    Pharmacists
Efficiency Indicators
  • 23
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 67%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 37 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 20 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices
General Indicators
No. of active clinical studies by study type
  • 64
    Active Clinical Trials
  • 247
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 4
    Clinical Trials initiated
  • 64
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 734
    No. of publications in indexed journals - last 5 full years
  • 100
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 269
    No. of available beds in the institution
  • 360
    No. of Physicians in the Institution
  • 620
    No. of Nurses in the Institution
  • 20
    No. of Pharmacists in the Institution
  • 4600 thousand
    No. of Inhabitants covered by the institution
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 56
    Researchers
  • 5
    Managers, Administrative, Legal and Financial
  • 4
    Study coordinators
  • 2
    Nurses
  • 1
    Pharmacists
Efficiency Indicators
  • 73
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 67%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 37 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 32 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices

Clinical Research Areas of interest

Clinical Research Areas of interest

  • Haematopathology
  • Breast Pathology
  • Dermatopathology
  • Gastrointestinal Pathology
  • Lung and Pleural Pathology
  • Uropathology
  • Paediatric Tumours
  • Basic & Translational Research
  • Head & Neck Pathology
  • Endocrine Pathology
  • Genital Pathology
  • Neuropathology
  • Familial Cancer
  • Epidemiology
  • Palliative Care and Neoplastic Pain
  • Oncology Nursing
  • Psycho-oncology
  • Radiation-oncology

Certifications

Certifications

  • ACSA (Agencia de Calidad Sanitaria de Andalucía) / DGS - Reference Centres
  • ESMO (European Society for Medical Oncology) - Comprehensive Oncology and Palliative Care Centre
  • OECI (Organisation of European Cancer Institutes) - Clinical Cancer Centre
  • ISO9001

Gallery

IPO Lisboa

IPO Lisboa

Working Group Participation

CONCORD Working Group

.

Consensus Guidelines on Gynaecological Cancer

biennial update

COVIDSurg

.

EORTC Breast Group

.

EORTC Quality of Life Group

.

EPICOVIDEHA working group

.

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer

.

European Consortium for Waldenström's Macroglobulinemia

.

European Oncology Nursing Society (EONS) Research Work Group

.

European Society for Blood and Marrow Transplantation (EBMT)

.

European Society of Anaesthesiology and Intensive Care (ESAIC)

.

Fondazione Italiana Linfomi (FIL)

.

GoCART Coalition Pharmacist Working Group

.

Inflammatory Bowel Disease Study Group (GEDII)

.

iNOVA4Health - Advancing Precision Medicine (Research Unit)

https://www.inova4health.com/

International Extranodal Lymphoma Study Group (IELSG)

.

International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPeN)

.

Italian Lymphoma Intergroup (IIL)

.

LS4FUTURE - Life Sciences for a Healthy and Sustainable Future (Associated Laboratory)

https://www.ls4future.pt/

Lymphoma Academic Research Organisation (LYSARC)

.

Melanoma Delphi Working Group

.

National Cancer Hub - Policy Group

Constituído por representantes das autoridades nacionais envolvidas nas políticas de estratégia e financiamento para a área da Saúde, de acordo com o Despacho n.º 11429/2021, de 19 de novembro.

National Cancer Hub - Stakeholders Group

O Stakeholders Group do National Cancer Hub tem como principal objetivo apoiar a implementação do Europe’s Beating Cancer Plan (EBCP) e da Missão Cancro através do fomento da participação portuguesa em iniciativas de estratégia e financiamento europeu e nacionais na área do cancro.

Constituído por representantes de entidades nacionais, públicas e privadas, relacionadas com diferentes aspetos da temática do cancro, incluindo instituições de saúde, academia, institutos de investigação, sociedades científicas, ordens profissionais, organizações de doentes, indústria, organizações da sociedade civil, entre outras.

Portuguese Association of Oncology Nursing (AEOP)

.

Portuguese Haematology Society (SPH)

.

Portuguese Lung Cancer Study Group (GECP)

.

Portuguese Paediatric Society (SPP)

.

Portuguese Society of Endocrinology, Diabetes and Metabolism (SPEDM) - Thyroid Study Group

.